TCTR20210811001
Recruiting
Phase 3
A Comparative Study of 2 doses of Botulinum Toxin A in Post Traumatic Trigeminal Neuropathic Pain
euroscience Research and Development Group, Khon Kaen University0 sites46 target enrollmentAugust 11, 2021
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Post Traumatic Trigeminal Neuropathic Pain (PTTNP)
- Sponsor
- euroscience Research and Development Group, Khon Kaen University
- Enrollment
- 46
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnosed with PPTTN according to the diagnostic criteria of International Classification of Orofacial Pain (ICOP, 2020\)
- •2\. Age of 20 to 65 years old
- •3\. Pain located intraorally, occurring unilaterally at the side of injury and is located at trigeminal nerve division of V2 and V3\.
- •4\. Patients experiencing pain score of more than or equal to 4 as measured by the Visual Analogue Scale (VAS) with continuous daily pain and those who do not respond to conventional pharmacotherapy within 3 months of treatment or has developed intolerable adverse reaction or detrimental systemic effects from medication
- •5\. Presence of other neuropathic symptoms such as allodynia and numbness are included.
- •6\. Participants are required to be in good general health
- •7\.Participants who can read, write and have understood the information regarding about the trial and the possible complications.
Exclusion Criteria
- •1\. Women who are pregnant or planning to be pregnant during the trial
- •2\. The presence of other orofacial neuropathic conditions (e.g. Trigeminal neuralgia, Post herpetic neuralgia, etc) and headache.
- •3\. Patients undergoing alternative treatment for PTTNP (e.g. acupuncture or herbal medicine)
- •4\. Patients who have presence of infection at the injection site
- •5\. Presence of medical conditions (e.g.motor neuropathic diseases and neuromuscular disorder) or use of any agent that might put patients at increased risk such as severe dysphagia and respiratory difficulties if exposed to BTX\-A
- •6\. Patients taking substances that might interfere with neuromuscular function
- •7\. Having uncontrolled systemic condition such as those who suffer from coagulopathy or severe heart, liver, kidney, or other organ dysfunction
- •8\. Patients with unstable mental illness and impaired cognitive.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 4
Effect of Two Difference Doses of Botulinum Toxin A on Infantile Esotropiastrabismus that can make patient amblyopia have to surgery but there are many of complication from surgical technique and sedation technique so intraocular muscle botulinum toxin injection and solve this problemstrabismus , botulinum toxin, infantile esotropiaTCTR20210210001faculty of medicine, khonkaen university78
Completed
N/A
Effects of Botulinum Toxin Type A in patients with chronic orofacial paiTemporomandibular Joint Dysfunction SyndromeC05.500.607.221.897RBR-8fsspyyFaculdade de Odontologia de Bauru, Universidade de São Paulo
Active, Not Recruiting
N/A
Botulinum Toxin injection in different group of muscles for the management of TMJ myofacial pain.Myofascial Pain - Dysfunction Syndrome of TMJMusculoskeletal - Other muscular and skeletal disordersACTRN12623000132640Damascus University26
Completed
Phase 3
Botulinum toxin injection vs Surgery for chronic anal fissureHealth Condition 1: K601- Chronic anal fissureCTRI/2020/03/023878Institute of General Surgery
Completed
N/A
A comparison of the effectiveness of botulinum toxin A and B in the treatment of adductor spasticity in adultservous System Diseases: Muscle spasticityNervous System DiseasesMuscle spasticityISRCTN92729017Department of Health